VANCOUVER, British Columbia (BUSINESS WIRE) $ABCL #AACR22 AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting. AbCellera’s pos.
Bebtelovimab neutralizes Omicron, including subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus dataVANCOUVER, British Columbia (BUSINESS WIRE) $ABCL #AbCellera AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government.
VANCOUVER, British Columbia (BUSINESS WIRE) $ABCL #antibodies AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time.A live audio webcast of the presenta.
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus dataPreviously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concernBebtelovimab binds to a rarely mutat.